Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Favorito

Orthopaedic Surgery Cincinnati, OH Medical Doctor

NPI 1306845151 CMS profile 58931

4460 Red Bank Expressway, Cincinnati, OH 45227

Open in the dashboard

General payments

$960,955

534 records reported · program years 2019–2025

Research payments

$30,200

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$167,455

1 holding reported · through program year 2025

Research they led as principal investigator

$196,636 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Paul Favorito of Cincinnati, OH is reported in the CMS Open Payments database as having received $960,955 across 534 general payments and $30,200 in research payments paid to them. Separately, studies naming them as principal investigator received $196,636 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $167,455 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $154,903 74
2024 General $162,266 111
2023 General $100,406 79
2022 General $83,949 56
2022 Research $30,200 1
2021 General $108,530 60
2020 General $105,740 46
2019 General $245,161 108
2025 Ownership $167,455 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Favorito
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Paul Favorito were reported at $154,903. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Paul Favorito Orthopaedic Surgery median Middle half National median
2019 $245,161 $644 $140–$2,844 $163
2020 $105,740 $312 $75–$1,860 $114
2021 $108,530 $520 $117–$2,495 $132
2022 $83,949 $598 $128–$2,731 $149
2023 $100,406 $461 $128–$2,264 $160
2024 $162,266 $497 $134–$2,475 $164
2025 $154,903 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $733,446 314 payments
  2. DePuy Synthes Products, Inc. $188,250 119 payments
  3. RTI Surgical, Inc. $18,212 5 payments
  4. Smith+Nephew, Inc. $9,305 19 payments
  5. Synthes GmbH $3,475 7 payments
  6. DePuy Synthes Sales Inc. $2,099 28 payments
  7. Heron Therapeutics, Inc. $1,500 1 payment
  8. Pacira Pharmaceuticals Incorporated $1,144 6 payments
  9. Legacy Ortho LLC $1,128 6 payments
  10. Arthrex, Inc. $629 11 payments
  11. Other $1,768 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $867,878 158 payments
  2. Travel and Lodging $58,143 146 payments
  3. Royalty or License $15,166 10 payments
  4. Food and Beverage $11,572 215 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,913 3 payments
  6. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $784 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $500 1 payment
Products named General payments · program years 2019–2025
  1. DELTA $194,197 51 payments
  2. EXPAREL $98,243 34 payments
  3. ARTHROSCOPE SHEATH $97,017 25 payments
  4. ABSOLUTE $95,867 24 payments
  5. BIOINTRAFIX $95,867 24 payments
  6. BIOLOX DELTA $53,254 30 payments
  7. ORTHOCORD $22,860 4 payments
  8. MATRIX HD $17,321 2 payments
  9. Gryphon Orthocord $14,855 12 payments
  10. INHANCE $7,290 47 payments
  11. Other $45,197 180 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $30,200 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

34

Median for Orthopedic Surgery: 203

Drug cost

$206

Median for Orthopedic Surgery: $1,433

Branded share of claims

67.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $178
Prednisone Generic 11 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$177,125

Of which drugs: $379

Medicare patients

443

Average age 73

Services billed

1,343

240 women, 203 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Ischemic heart disease 28%
Diabetes 18%
Depression 18%
Chronic kidney disease 15%
Cancer 15%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 33 84 $379

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

535 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record